Literature DB >> 22258711

Choline PET/CT compared with bone scintigraphy in the detection of bone metastases in prostate cancer patients.

Mohsen Beheshti, Werner Langsteger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22258711     DOI： 10.1007/s00259-011-2046-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  8 in total

1.  Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer.

Authors:  H Schirrmeister; G Glatting; J Hetzel; K Nüssle; C Arslandemir; A K Buck; K Dziuk; A Gabelmann; S N Reske; M Hetzel
Journal:  J Nucl Med       Date:  2001-12       Impact factor: 10.057

2.  [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy.

Authors:  Maria Picchio; Elena Giulia Spinapolice; Federico Fallanca; Cinzia Crivellaro; Giampiero Giovacchini; Luigi Gianolli; Cristina Messa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-20       Impact factor: 9.236

3.  Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer.

Authors:  Takako Nakai; Chio Okuyama; Takao Kubota; Kei Yamada; Yo Ushijima; Keiko Taniike; Takako Suzuki; Tsunehiko Nishimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-20       Impact factor: 9.236

Review 4.  Positron emission tomography and bone metastases.

Authors:  Ignac Fogelman; Gary Cook; Ora Israel; Hans Van der Wall
Journal:  Semin Nucl Med       Date:  2005-04       Impact factor: 4.446

Review 5.  The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast.

Authors:  Werner Langsteger; Martin Heinisch; Ignac Fogelman
Journal:  Semin Nucl Med       Date:  2006-01       Impact factor: 4.446

6.  The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.

Authors:  Mohsen Beheshti; Reza Vali; Peter Waldenberger; Friedrich Fitz; Michael Nader; Josef Hammer; Wolfgang Loidl; Christian Pirich; Ignac Fogelman; Werner Langsteger
Journal:  Mol Imaging Biol       Date:  2009 Nov-Dec       Impact factor: 3.488

7.  Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study.

Authors:  Mohsen Beheshti; Reza Vali; Peter Waldenberger; Friedrich Fitz; Michael Nader; Wolfgang Loidl; Gabriele Broinger; Franz Stoiber; Ignac Foglman; Werner Langsteger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-09       Impact factor: 9.236

Review 8.  Prostate cancer: role of SPECT and PET in imaging bone metastases.

Authors:  Mohsen Beheshti; Werner Langsteger; Ignac Fogelman
Journal:  Semin Nucl Med       Date:  2009-11       Impact factor: 4.446
  8 in total
  2 in total

1.  (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.

Authors:  Ugo De Giorgi; Paola Caroli; Emanuela Scarpi; Vincenza Conteduca; Salvatore Luca Burgio; Cecilia Menna; Andrea Moretti; Riccardo Galassi; Lorena Rossi; Dino Amadori; Giovanni Paganelli; Federica Matteucci
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-26       Impact factor: 9.236

Review 2.  PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data.

Authors:  Stefano Fanti; Silvia Minozzi; Paolo Castellucci; Sara Balduzzi; Ken Herrmann; Bernd Joachim Krause; Wim Oyen; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-09       Impact factor: 9.236
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.